Am J Transplant, Volume 17, Suppl 3 Archives - Page 181 of 181 - ATC Abstracts

2017 American Transplant Congress
Infusion of Polyclonal Tregs Modulates Subclinical Kidney Transplant Inflammation: Final Report of TASK Pilot Trial.
S. Chandran, Q. Tang, M. Sarwal, Z. Laszik, A. Putnam, T. Sigdel, E. Tavares, J. Bluestone, F. Vincenti.
UCSF, San Francisco
Purpose:Treg therapy can reverse established inflammation in animal models. We conducted a pilot safety & feasibility trial of Treg therapy for subclinical kidney transplant inflammation.Methods:Peripheral…
2017 American Transplant Congress
Pre-Transplant Circulating TNFR2+ Regulatory T Cells Predict Acute Rejection within the First 6 Months After Kidney Transplantation.
M.-T. Nguyen,¹ S. Sahakian,² S. Liu,² Y. Wang,² J. Tchervenkov,² S. Paraskevas.²
¹Department of Surgery, Columbia University, New York, NY; ²Department of Surgery, McGill University, Montreal, QC, Canada
Background: Acute rejection (AR) mostly occurs during the first 6 months after kidney transplantation and contributes importantly to graft loss. Diagnosis relies on changes in…
2017 American Transplant Congress
Molecular Analysis of Acute Rejection in Formalin-Fixed Paraffin-Embedded Clinical Face Transplant Biopsies.
T. Win,¹ B. Dyring-Andersen,¹ V. Barrera,² S. Ho Sui,² R. Lopdrup,¹ H. Kiwanuka,¹ N. Murakami,¹ J. Teague,¹ E. Lowry,¹ E. Bueno,¹ A. Chandraker,¹ L. Riella,¹ B. Pomahac,¹ R. Clark.¹
¹Brigham and Women's Hospital, Boston, MA; ²Harvard T.H. Chan School of Publich Health, Boston
BackgroundDiagnosis of acute rejection in face transplants relies on the histological evaluation of allograft skin biopsies using BANFF classification, an approach with significant limitations including…
2017 American Transplant Congress
Necroptotic Cellular Death Modulates TNFα Mediated Inflammation and Cardiac Allograft Rejection in Mice.
R. Ang, P. Heeger, A. Ting.
Immunology Institute, Icahn School of Medicine at Mount Sinai, NYC, NY
While graft injury following cold ischemia reperfusion (IR) can accelerate graft rejection, mechanisms are incompletely understood. Evidence indicates that posttransplant IR injury is associated with…
2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
G. de Graav,¹ C. Baan,¹ M. Clahsen-van Groningen,² R. Kraaijeveld,¹ M. Dieterich,¹ W. Verschoor,¹ D. Roelen,³ M. Cadogan,¹ J. van de Wetering,¹ J. van Rosmalen,⁴ W. Weimar,¹ D. Hesselink.¹
¹Internal Medicine, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ²Pathology, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ³Immunohematology and Blood Transfusion, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ⁴Biostatistics, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…
2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
S. Kilaru,¹ E. Tapper,² M. Curry.³
¹Medicine, NYU School of Medicine, New York, NY; ²Medicine, University of Michigan, Ann Arbor, MI; ³Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…